Literature DB >> 17327215

Imaging repressed memories in motor conversion disorder.

Richard A A Kanaan1, Tom K J Craig, Simon C Wessely, Anthony S David.   

Abstract

OBJECTIVES: Conversion disorders comprise neurologically unexplained symptoms with a presumed psychiatric cause, though a neuroscientific basis for this is lacking. The standard psychiatric model of conversion holds that events and processes that might explain the symptoms are, by hypothesis, either repressed or subconscious. This makes assessments based on subjective reports unreliable. We circumvent this by using a standardized method to quantify stressful life events and by assessing objectively the neural correlates of emotion processing.
METHODS: Single case study of a 37-year-old woman with clinically repressed recall and unexplained right-sided paralysis. We describe the application of the Life Events and Difficulties Schedule (LEDS) to her history, and a novel functional magnetic resonance imaging (fMRI) procedure exploring emotion processing of traumatic and control memories.
RESULTS: While in the scanner, cued recall of the clinically repressed event was associated with regional brain activations characteristic of emotional arousal, including the amygdala and right inferior frontal lobe, when compared with an equally severe event from the patient's past, as rated by the LEDS. Such recall was also associated with decreased motor activity in the area corresponding to the subjectively paralyzed limb.
CONCLUSION: This case study provides neuroimaging evidence for a connection between traumatic events and ongoing neurological symptoms.

Entities:  

Mesh:

Year:  2007        PMID: 17327215     DOI: 10.1097/PSY.0b013e31802e4297

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  20 in total

1.  Emotional stimuli and motor conversion disorder.

Authors:  Valerie Voon; Christina Brezing; Cecile Gallea; Rezvan Ameli; Karin Roelofs; W Curt LaFrance; Mark Hallett
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

Review 2.  The role of the anterior and midcingulate cortex in the neurobiology of functional neurologic disorder.

Authors:  Juan Pablo Ospina; Rozita Jalilianhasanpour; David L Perez
Journal:  Handb Clin Neurol       Date:  2019

3.  Treatment of conversion disorder in the 21st century: have we moved beyond the couch?

Authors:  Patricia I Rosebush; Michael F Mazurek
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

4.  The involuntary nature of conversion disorder.

Authors:  V Voon; C Gallea; N Hattori; M Bruno; V Ekanayake; M Hallett
Journal:  Neurology       Date:  2010-01-19       Impact factor: 9.910

5.  The functional neuroimaging correlates of psychogenic versus organic dystonia.

Authors:  Anette E Schrag; Arpan R Mehta; Kailash P Bhatia; Richard J Brown; Richard S J Frackowiak; Michael R Trimble; Nicholas S Ward; James B Rowe
Journal:  Brain       Date:  2013-03       Impact factor: 13.501

6.  A Bayesian account of 'hysteria'.

Authors:  Mark J Edwards; Rick A Adams; Harriet Brown; Isabel Pareés; Karl J Friston
Journal:  Brain       Date:  2012-05-28       Impact factor: 13.501

7.  The amygdalo-motor pathways and the control of facial expressions.

Authors:  Katalin M Gothard
Journal:  Front Neurosci       Date:  2014-03-19       Impact factor: 4.677

Review 8.  Imaging psychogenic movement disorders.

Authors:  Arpan R Mehta; James B Rowe; Anette E Schrag
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

9.  Functional neuroimaging of conversion disorder: the role of ancillary activation.

Authors:  Matthew J Burke; Omar Ghaffar; W Richard Staines; Jonathan Downar; Anthony Feinstein
Journal:  Neuroimage Clin       Date:  2014-09-30       Impact factor: 4.881

10.  Emotion-motion interactions in conversion disorder: an FMRI study.

Authors:  Selma Aybek; Timothy R Nicholson; Owen O'Daly; Fernando Zelaya; Richard A Kanaan; Anthony S David
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.